The global vascular stents market is projected to grow at a rate of 6-8% over the next five years. Key drivers of this growth include the increasing prevalence of cardiovascular diseases (CVDs), advancements in stent technology, a shift toward minimally invasive procedures, favorable reimbursement policies, and an aging population. However, challenges such as the high cost of stents, potential complications and risks associated with their use, strict regulatory approval requirements, and the availability of alternative treatments may pose obstacles to market expansion.
Download Sample PDF: https://meditechinsights.com/vascular-stents-market/request-sample/
Competitive Landscape
The global vascular stents market is highly competitive, with major players including:
- Abbott Laboratories
- B. Braun SE
- Becton, Dickinson, and Company
- Biotronik SE & Co. KG
- Boston Scientific Corporation
- Medtronic Plc
- Stryker Corporation
- Terumo Corporation
These companies are focusing on both technological innovation and strategic partnerships to strengthen their position in the market.
Vascular Stents Market Overview
Vascular stents are small, expandable tubes made of metal or polymer mesh, designed to keep narrowed or blocked blood vessels open. Typically used in angioplasty, a minimally invasive procedure, stents are inserted via a balloon-tipped catheter to widen the affected vessel. Once the artery is open, the stent remains in place to provide structural support, preventing restenosis, the re-narrowing of the vessel. Drug-eluting stents (DES) are a common type, releasing medication to further reduce the risk of restenosis.
Rising Prevalence of Cardiovascular Diseases (CVDs) to Drive Market Growth
The global prevalence of cardiovascular diseases (CVDs), including coronary artery disease, peripheral artery disease, and atherosclerosis, is on the rise. Contributing factors include aging populations, unhealthy lifestyles, obesity, and diabetes. According to the World Health Organization (WHO), CVDs are the leading cause of death worldwide, responsible for an estimated 17.9 million deaths annually, accounting for 32% of global fatalities. Of these, 85% are attributed to heart attacks and strokes, which often lead to the narrowing or blockage of arteries.
Interventions like angioplasty with stenting are critical to restoring blood flow. Vascular stents, particularly drug-eluting and bioresorbable types, help prevent restenosis after balloon angioplasty, significantly improving patient outcomes. As the burden of CVDs increases globally, demand for minimally invasive procedures, such as stenting, is growing. This trend is supported by better healthcare infrastructure and increased awareness of cardiovascular health in both developed and emerging markets, contributing to the expected growth of the vascular stents market.
Consultant Cardiologist, Leading Hospital Group, United States:
“There is a growing preference for minimally invasive surgeries due to their associated benefits, such as reduced recovery times and lower complication rates. This trend is driving the adoption of vascular stents over traditional surgical methods.”
Growing Preference for Minimally Invasive Procedures
Minimally invasive techniques like percutaneous coronary intervention (PCI), which involves placing vascular stents, are increasingly preferred for treating CVDs such as coronary artery disease and peripheral artery disease. These procedures offer numerous advantages over traditional surgery, including faster recovery times, reduced complication risks, shorter hospital stays, and minimal scarring, all of which appeal to patients and healthcare providers alike.
Advancements in stent technology, including drug-eluting and bioresorbable stents, have further improved the success rates of these minimally invasive procedures, reducing the likelihood of restenosis and enhancing long-term safety. As a result, stenting has become a reliable option, even for patients who are not candidates for more invasive surgeries like coronary artery bypass grafting (CABG).
While the trend is especially prominent in developed regions with advanced healthcare systems, it is also gaining traction in emerging markets, where rising awareness and improving healthcare infrastructure are increasing access to stenting procedures. This growing preference for minimally invasive interventions is expected to drive the demand for vascular stents, positioning them as a central component of CVD treatment and fueling market growth.
Download Sample PDF: https://meditechinsights.com/vascular-stents-market/request-sample/
Expansion of Bioabsorbable Stents: A Major Market Opportunity
Bioabsorbable stents, designed to dissolve naturally over time, represent a significant opportunity in the vascular stents market. Unlike traditional metal stents, which remain in the body permanently, bioabsorbable stents gradually degrade, reducing long-term complications like stent thrombosis, inflammation, and the need for additional interventions. These stents are particularly beneficial for younger patients or those with less severe blockages, where long-term stent presence could pose risks.
The growing awareness of the advantages of bioabsorbable stents, combined with advancements in materials and clinical outcomes, is driving their adoption. The increasing demand for minimally invasive solutions and innovative treatments in cardiovascular care, along with rising healthcare investments in emerging markets, further supports the expansion of bioabsorbable stents. As these stents become more accessible and affordable, they are poised to capture a significant share of the vascular stents market, contributing to its overall growth.
North America: Key Growth Region
North America is expected to be a major growth driver in the vascular stents market, thanks to several key factors. The region has a high prevalence of CVDs, fueled by lifestyle-related conditions such as obesity, diabetes, and hypertension, as well as an aging population. This increases the demand for vascular stents. North America also boasts advanced healthcare infrastructure and access to cutting-edge medical technologies, making it a hub for adopting innovative stent solutions like drug-eluting and bioresorbable stents.
Strong reimbursement policies in the region make stenting procedures more accessible, further driving market growth. Additionally, North American companies are leading research and development efforts, continuously improving stent technology. With increasing awareness of minimally invasive procedures and the availability of well-established healthcare facilities, North America is positioned to remain a key driver in the global vascular stents market.
Meanwhile, the Asia-Pacific (APAC) region is witnessing rapid growth due to an aging population and increasing prevalence of CVDs. Improvements in healthcare infrastructure, rising healthcare spending, and government investments in countries like China, India, and Japan are expanding access to stenting procedures, thereby boosting demand for vascular stents.
Market Segmentation
Product Type Segment Analysis:
The vascular stents market includes products such as:
- Coronary Stents
(including peripheral, carotid, renal, femoral, iliac artery stents, and other peripheral stents) - EVAR Stent Grafts
(including abdominal and thoracic aortic aneurysm stent grafts)
Coronary stents represent the largest segment due to their extensive use in treating coronary artery disease, a leading global health concern. This segment benefits from high procedural volumes, technological advancements like drug-eluting stents, and favorable clinical outcomes. The EVAR stent graft segment, particularly for abdominal aortic aneurysms, is also expected to see significant growth as awareness of endovascular techniques increases, offering less invasive treatment options for patients with aortic aneurysms.
End-User Segment Analysis:
The vascular stents market can be segmented by end users, including:
- Hospitals: The largest segment, due to their comprehensive facilities and ability to handle complex procedures.
- Cardiac Centers: Specializing in cardiovascular interventions.
- Ambulatory Surgical Centers (ASCs): Gaining popularity due to their cost-effectiveness, shorter patient wait times, and convenience for outpatient procedures.
ASCs are becoming a preferred option for elective vascular interventions, driving their growth in the market, particularly with the increasing trend toward same-day discharge and minimally invasive procedures.
Organic and Inorganic Growth Strategies
Companies in the vascular stents market are pursuing both organic and inorganic growth strategies such as acquisitions, partnerships, and new product launches. Examples include:
- Boston Scientific’s acquisition of Silk Road Medical in September 2024 for approximately USD 1.26 billion, enhancing its portfolio with stroke prevention technologies.
- Abbott’s launch of the XIENCE Sierra Everolimus-eluting coronary stent system in India in May 2024, designed to improve safety and efficacy in treating blocked coronary arteries.
- Terumo India’s launch of the Ultimaster Nagomi drug-eluting stent in December 2023 for treating coronary artery disease.
- Medtronic’s launch of the Onyx Frontier drug-eluting coronary stent in August 2022, following CE Mark approval.
These activities reflect the ongoing efforts of industry players to innovate and expand their market share, further driving the growth of the vascular stents sector.
Browse Report: https://meditechinsights.com/vascular-stents-market/
About Medi-Tech Insights ;
Medi-Tech Insights is a healthcare-focused business research & insights firm. Our clients include Fortune 500 companies, blue-chip investors & hyper-growth start-ups. We have completed 100+ projects in Digital Health, Healthcare IT, Medical Technology, Medical Devices & Pharma Services in the areas of market assessments, due diligence, competitive intelligence, market sizing and forecasting, pricing analysis & go-to-market strategy. Our methodology includes rigorous secondary research combined with deep-dive interviews with industry-leading CXO, VPs, and key demand/supply side decision-makers.
Contact:
Ruta Halde
Associate, Medi-Tech Insights
+32 498 86 80 79
